CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 437,935	$ 492,860
Marketable securities	4,741	4,941
Prepaid expenses	4,868	5,354
Other current assets	1,313	1,348
Total current assets	448,857	504,503
Property and equipment, net of accumulated depreciation of $5,113 and $4,316 at March 31, 2019 and December 31, 2018, respectively	35,448	23,469
Other long-term assets	269	68
Total Assets	484,574	528,040
Current Liabilities:
Accounts payable and accrued expenses	53,926	31,722
Liability related to sale of future royalties - current	2,657	0
Lease liability - current	298	0
Total current liabilities	56,881	31,722
Convertible senior notes, net	7,068	7,055
Liability related to sale of future royalties - non-current	228,600	221,295
Other long-term liabilities	10,221	2,119
Total Liabilities	302,770	262,191
Commitments and Contingencies (Note 10)
Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at March 31, 2019 and December 31, 2018	0	0
Common stock, $0.01 par value; authorized 250,000,000 shares; issued 191,509,289 shares and outstanding 191,389,668 shares at March 31, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018	1,915	1,905
Capital contributed in excess of par	1,224,066	1,219,237
Treasury stock, at cost: 119,621 shares at March 31, 2019 and 34,725 shares at December 31, 2018	(2,095)	(824)
Accumulated deficit	(1,040,553)	(953,216)
Accumulated other comprehensive loss	(560)	(351)
Total Immunomedics, Inc. stockholders' equity	182,773	266,751
Noncontrolling interest in subsidiary	(969)	(902)
Total stockholders' equity	181,804	265,849
Total Liabilities and Stockholders' Equity	$ 484,574	$ 528,040